Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Core Viewpoint - Acurx Pharmaceuticals, Inc. has announced a definitive agreement for the purchase and sale of 2,463,058 shares of its common stock at a price of $1.015 per share, along with a concurrent private placement of unregistered warrants to purchase the same number of shares at an exercise price of $0.90 per share [1][2]. Group 1: Offering Details - The total gross proceeds from the offering are expected to be approximately $2.5 million before deducting fees and expenses [2]. - The closing of the offering is anticipated to occur on or about January 7, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and other general corporate purposes [2]. Group 3: Company Overview - Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics targeting difficult-to-treat bacterial infections [6]. - The company's lead product candidate, ibezapolstat, is ready for Phase 3 trials for the treatment of C. difficile infection, with plans for international clinical trials this year [6]. - Acurx's research and development pipeline includes antibiotic candidates targeting Gram-positive bacteria, including MRSA, VRE, and anthrax [6].